Ocular Therapeutix, Inc. (OCUL)

NASDAQ: OCUL · IEX Real-Time Price · USD
4.06
+0.04 (1.00%)
Jul 1, 2022 11:56 AM EDT - Market open

Company Description

Ocular Therapeutix, Inc., a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology.

The company markets ReSure Sealant, an ophthalmic device to prevent wound leaks in corneal incisions following cataract surgery; and DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis.

It is also developing OTX-TKI, an axitinib intravitreal implant that is in phase 1 clinical trials for the treatment of wet age-related macular degeneration and other retinal diseases; OTX-TIC, a travoprost intracameral implant, which is in phase 2 clinical trials for the treatment of open-angle glaucoma or ocular hypertension; OTX-CSI, a cyclosporine intracanalicular insert that has completed phase 2 clinical trials for the treatment of dry eye disease; and OTX-DED, a dexamethasone intracanalicular insert, which is in phase 2 clinical trials for the short-term treatment of the signs and symptoms of dry eye disease.

The company has a strategic collaboration with Regeneron Pharmaceuticals, Inc. (Regeneron) for the development and commercialization of products using the Company's sustained-release hydrogel in combination with Regeneron's large molecule VEGF-targeting compounds for the treatment of retinal diseases; and AffaMed Therapeutics Limited for the development and commercialization of DEXTENZA and OTX-TIC, as well as a discovery collaboration with Mosaic Biosciences to identify new targets and therapeutic agents for the treatment of dry age-related macular degeneration (dMAD).

Ocular Therapeutix, Inc. was incorporated in 2006 and is headquartered in Bedford, Massachusetts.

Ocular Therapeutix, Inc.
Ocular Therapeutix Logo
Country United States
Founded 2006
IPO Date Jul 25, 2014
Industry Pharmaceuticals
Sector Health Care
Employees 228
CEO Antony Mattessich

Contact Details

Address:
24 Crosby Dr
Bedford, Massachusetts 01730-1402
United States
Phone 781 357 4000
Website ocutx.com

Stock Details

Ticker Symbol OCUL
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency US Dollars
CIK Code 0001393434
CUSIP Number 67576A100
ISIN Number US67576A1007
Employer ID 20-5560161
SIC Code 2834

Key Executives

Name Position
Antony Mattessich President, Chief Executive Officer and Director
Donald Notman Jr. Chief Financial Officer
Dr. Michael H. Goldstein M.B.A., M.D., M.M. President of Ophthalmology and Chief Medical Officer
Dr. Peter K. Jarrett Ph.D. Chief Scientific Officer
Philip C. Strassburger General Counsel
William H. Ransone II Vice President of Global Sales and Marketing
Tracy Smith Vice President of Human Resources
Scott Corning Senior Vice President of Commercial
Christopher G. White Chief Business Officer
Dr. Rabia Gurses Ozden M.D. Senior Vice President of Clinical Development

Latest SEC Filings

Date Type Title
Jun 21, 2022 4 Statement of changes in beneficial ownership of securities
Jun 21, 2022 4 Statement of changes in beneficial ownership of securities
Jun 21, 2022 4 Statement of changes in beneficial ownership of securities
Jun 21, 2022 4 Statement of changes in beneficial ownership of securities
Jun 21, 2022 4 Statement of changes in beneficial ownership of securities
Jun 21, 2022 4 Statement of changes in beneficial ownership of securities
Jun 17, 2022 8-K Current report
Jun 8, 2022 8-K Current report
May 16, 2022 4 Statement of changes in beneficial ownership of securities
May 16, 2022 4 Statement of changes in beneficial ownership of securities